CD20 Protein, Human, Recombinant (His & Avi)

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.

CD20 Protein, Human, Recombinant (His & Avi)

パッケージサイズ	在庫状況	単価(税別)
100 μg	約5 days	￥ 107,000
500 μg	約5 days	￥ 424,500
1 mg	約5 days	￥ 711,500

バルクのお問い合わせ

説明

Species	Human
Expression Host	E. coli
Tag	C-His-Avi
Accession Number	P11836-1
別名	MS4A2, Ly-44, LEU-16, MS4A1, Bp35, CD20 receptor, CVID5, MS4A-1, B1, S7, CD20S7, CD20
Construction	Ile141-Ser188
Protein Purity	> 95% as determined by Tris-Bis PAGE
分子量	16.8 kDa (predicted) same as Tris-Bis PAGE result.

Endotoxin	< 1 EU/μg by the LAL method.
Formulation	Supplied as 0.22 μm filtered solution in 20 mM PB, 10% Glycerol, 0.4M Urea, 1 mM GSH, 0.1 mM GSSG (pH 7.0).
Stability & Storage	It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
Research Background	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.

参考文献

1. Ma D, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66. 2. Jager U, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

CD20 Protein, Human, Recombinant (His & Avi)

参考文献

Calculator

技術サポート

Keywords